Pearl Steinzor

Steven Daveluy, MD, discusses 3-year findings that show 86% of patients remained HS flare-free throughout treatment, reinforcing the case for early intervention.

Medically tailored meals and produce show feasibility but no reduction in 90-day readmissions, according to one study.

The FDA has approved the first generic versions of dapagliflozin, expanding access to a widely used SGLT2 inhibitor.

Proactive adverse effect management helps patients with skin cancer stay on treatment longer, according to Todd Schlesinger, MD.

Key session speakers and abstract presenters share their highlights of attending AAD 2026.

Evaluation of more than 65,000 trials and 350,000 investigator sites highlights significant exposure in oncology and late-stage development.

New real-world data highlight sustained response and remission rates with esketamine nasal spray for patients with treatment-resistant depression.

Lauren Madigan, MD, shares open-label extension results demonstrating sustained improvements with avapritinib in patients with indolent systemic mastocytosis.

Melinda Gooderham, MD, MSc, FRCPC, discusses findings from the Latitude PsO 3001 and Latitude PsO 3002 studies evaluating zasocitinib.

Todd Schlesinger, MD, discusses how new immunotherapies and multidisciplinary care are reshaping treatment approaches for patients with advanced skin cancers.

Martina Porter, MD, discusses long-term results from the phase 3 STOP-HS program evaluating povorcitinib in patients with hidradenitis suppurativa.

April Armstrong, MD, MPH, discusses findings from the TRACE study, which evaluated the real-world effectiveness of tralokinumab in patients with skin of color with AD.

Linda Stein Gold, MD, shares efficacy and safety findings from the ICONIC-ADVANCE studies in moderate to severe psoriasis.

Clinicians need to adjust their diagnostic lens and counseling strategies in patients with skin of color, explained Joseph Lam, MD.

James Song, MD, discusses the direction teledermatology is heading and how more inclusive clinical trials can improve outcomes for patients of color.

Linda Stein Gold, MD, shares recent findings from the pooled phase 3 analysis of the ADORING 1 and ADORING 2 trials for atopic dermatitis.

John Barkett, MBA, discusses how health care price transparency can affect both patient out-of-pocket costs and overall health care spending.

Christopher Shade, PhD, shares insights for managed care leaders on oral peptide therapies.

Findings show sustained reductions in HbA1c, weight, blood pressure, inflammation, and lipids in patients with T2D and ASCVD or CKD.

Making health care prices public was supposed to cut costs. The reality is more complicated.

Active or severe atopic dermatitis throughout childhood and adolescence does not increase cardiometabolic risk, according to new research.

Conduction system pacing was found to be inferior to biventricular pacing for key outcomes in HFrEF with left bundle-branch block, despite lower costs.

Pediatric health coaching offers a workforce-driven solution to provide support that traditional care models often lack, with the potential to improve outcomes and reduce long-term costs.

James Song, MD, previews new oral therapies and guidelines psoriasis, atopic dermatitis, and chronic spontaneous urticaria.

New research shows that cardiovascular protection from GLP-1 receptor agonists such as semaglutide and tirzepatide diminishes within months of discontinuation.

Factual tone, credible sources, and clinician representation increase trust and engagement, while humor may undermine vaccine messaging effectiveness.

Study supports broader use of transient elastography to detect advanced liver fibrosis in patients with metabolic dysfunction–associated steatotic liver disease.

Long-term adherence to healthy behaviors reduces the risk of cardiovascular disease and type 2 diabetes, even among individuals taking antihypertensive medications.

Vutrisiran kept a favorable safety profile in patients with transthyretin amyloidosis treated for up to 58 months, with AE rates comparable to placebo and no new safety concerns.